Upload Avatar (500 x 500)
Yu Cao
College of Chemical Biology and Biotechnology
Peking University
Guangdong
Language: English, Chinese
Cancer
Immunotherapy
Antibody
Precision
Medicine
Design
Tumor
Therapy
Cell
Biotechnology
Areas of Focus
- Cancer Immunotherapy
- Precision Medicine
- Antibody Design
Work Experience
- 2022-present - Shenzhen Bay Laboratory - Special Researcher
- 2017-present - Peking University Shenzhen Graduate School - Group Leader, Distinguished Researcher
- 2016-2017 - Sorrento Therapeutics, USA - Senior Scientist
- 2013-2016 - The Scripps Research Institute - Assistant Researcher
- 2007-2013 - MD Anderson Cancer Center - Postdoctoral Fellow
Academic Background & Achievements
- 2001-2007 Ph.D. in Science: Nankai University
- 1996-2000 Bachelor of Science: Liaoning University
Publications
- A novel loop-structure-based bispecific CAR that targets CD19 and CD22 with enhanced therapeutic efficacy against B-cell malignances, Lijun Zhao, Shuhong Li, Xiaoyi Wei, Xuexiu Qi, Qiaoru Guo, Licai Shi, Ji-Shuai Zhang, Jun Li, Ze-Lin Liu, Zhi Guo, Hongyu Zhang, Jia Feng, Yuanyuan Shi, Suping Zhang, Yu J. Cao, 2024
- Applications of genetic code expansion technology in eukaryotes, Qiao-ru Guo, Yu J. Cao, 2024
- A Novel Her2/VEGFR2/CD3 trispecific antibody with an optimal structural design showed improved T-cell-redirecting antitumor efficacy, Dong Liu, Xuexiu Qi, Xiaoyi Wei, Lijun Zhao, Xuechun Wang, Shuhong Li, Zhidong Wang, Lisai Shi, Jie-an Xu, Mei Hong, Zhong Liu, Lili Zhao, Xiankun Wang, Bo Zhang, Yuhan Zhang, Feng Wang, Yu J. Cao, 2022
- A novel CD19/CD22/CD3 trispecific antibody enhances therapeutic efficacy and overcomes immune escape against B-ALL, Lijun Zhao, Shuhong Li, Xiaoyi Wei, Xuexiu Qi, Dong Liu, Lei Liu, Feiqiu Wen, Ji-shuai Zhang, Feng Wang, Ze-lin Liu, Yu J. Cao, 2022
- Synthesis of precision antibody conjugates using proximity-induced chemistry, Yu J. Cao, Chenfei Yu, Kuan-Lin Wu, Xuechun Wang, Dong Liu, Zeru Tian, Lijun Zhao, Xuexiu Qi, Axel Loredo, Anna Chung, Han Xiao, 2021
- Switchable CAR-T Cells Outperformed Traditional Antibody-Redirected Therapeutics Targeting Breast Cancers, Yu J. Cao, Xuechun Wang, Zhidong Wang, Lijun Zhao, Shuhong Li, Zhuxia Zhang, Xiaoyi Wei, Hwayoung Yun, Sei-hyun Choi, Zhong Liu, Lili Zhao, Stephanie A. Kazane, 2021
- Adoptive cell therapy targeting neoantigens: a frontier for cancer research, Zhidong Wang, Yu J. Cao, 2020
- Engineered T Cell Therapy for Cancer in the Clinic, Lijun Zhao, Yu J. Cao, 2019
- A tumor-targeted immune checkpoint blocker, Yuhan Zhang, Changming Fang, Rongsheng E. Wang, Ying Wang, Hui Guo, Chao Guo, Lijun Zhao, Shuhong Li, Xia Li, Peter G. Schultz, Yu J. Cao, Feng Wang, 2019
- Development of a human immuno-oncology therapeutic agent targeting HER2: targeted delivery of granzyme B, Lawrence H. Cheung, Yunli Zhao, Ana Alvarez-Cienfuegos, Khalid A. Mohamedali, Yu J. Cao, Walter N. Hittelman, Michael G. Rosenblum, 2019
